On September 15th, Al Frost, Chief Executive Officer of OPKO Health, Inc. (NASDAQ: OPK), purchased 200,000 shares of the company’s stock. When purchasing shares of stock for a total of 412,000.00 dollars, the average price paid per share was $2.06. As a direct result of the transaction, the Chief Executive Officer now owns 197,456,694 shares of the firm. Based on the current stock price, these shares have a value of around $406,760,789.64. The transaction was disclosed to the public through a file that was filed with the SEC, which can be located on the website of the SEC. Furthermore, and more recently, Phillip M. et al. Frost has been involved in the following transaction(s): When trading started on Friday, the price of one share of OPKO Health was $2.06 per share.
The company has a simple moving average of $2.43 for the last fifty days and a simple moving average of $2.82 in the previous two hundred days. The price-to-earnings ratio for the stock is currently -7.10, and it has a market value of $1.59 billion. The stock’s beta value is 1.75. The ratio of the current ratio to the quick ratio is 1.91, whereas the ratio of the current ratio to the quick ratio is 2.30. The ratio of debt to equity is 0.12. During the previous year, the price of OPKO Health, Inc. ranged from its lowest point of $2.04 to its most significant point of $5.25. On Thursday, August 4th, the most recent earnings report for OPKO Health was made public. This report relates to the company’s stock, which is traded on the NASDAQ under the ticker code OPK. The earnings per share (EPS) that the biotechnology company announced for the quarter were $0.04, which was $0.02 less than what was projected by the consensus, which was $0.02 for the quarter.
Analysts projected that total sales for the quarter would fall somewhere between $326.87 million to $309.90 million. OPKO Health had a negative net margin, which came in at -14.18%, and a negative return on equity, which came in at -7.72%. Both of these figures represent a loss for the company. The quarterly revenues of OPKO Health experienced a decrease of 30.0% when compared to the same quarter in the prior year. The corporation incurred $0.03 per share during the same year. Analysts who participate in market research predict that OPKO Health, Inc. will lose $0.38 per share in 2018. Recently, hedge funds have been very active in the stock market of the corporation, buying and selling shares back and forth. During the first three months of this year, the Swiss National Bank increased the percentage of OPKO Health shares it owned by 7.5%.
During the most recent quarter, the Swiss National Bank increased its shares in the biotechnology business by 72,900. This brought the total number of shares it holds in the company to 1,047,200, which has a value of $3,602,000. During the fourth quarter of 2018, BNP Paribas Arbitrage SA completed the purchase of an additional 19.2% stake in OPKO Health. BNP Paribas Arbitrage SA increased its holdings in the stock of the biotechnology business by purchasing an additional 26,707 shares during the most recent fiscal quarter. This brings the total number of shares the company has acquired to 165,928, with an associated value of $798,000. In addition, the acquisition of a new stake in OPKO Health by Columbia Asset Management cost roughly $67,000 during the fourth quarter. E Fund Management Co. Ltd. boosted the amount of OPKO Health stock owned by 190.1% during the first three months of 2018.
After purchasing an additional 53,299 shares over the most recent quarter, E Fund Management Co., Ltd. now has a total of 81,338 shares of the business with a market value of $280,000. The company’s market cap is currently at $280,000. In addition, Levin Capital Strategies LP made a fresh investment in OPKO Health shares during the first three months of 2018. The value of this investment was about $52,000. Currently, 27.83% of the company’s shares are owned by institutional investors and hedge funds combined. In a separate research report published on Friday, August 5th, Piper Sandler lowered their price target on OPKO Health shares from $5.00 to $4.00 and gave the company an “overweight” rating in a separate research report. In addition, Piper Sandler maintained their “overweight” rating on the business.
A healthcare company known as OPKO Health, Inc. operates in several countries, including the United States of America, Ireland, Chile, Spain, Israel, Mexico, and other countries. This company specializes in diagnostics and drugs. BioReference Laboratories, which the company’s Diagnostics division manages, offer testing services for the detection, diagnosis, assessment, monitoring, and treatment of disease. These services can be obtained by contacting BioReference Laboratories. Employers and governmental bodies, medical offices and clinics, hospitals, and private clinics, can take advantage of these services. Some of the services included in this category include esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare, the category’s website states.